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Abstract
Background: Surgery and stereotactic ablative radiotherapy (SABR) are both curative treatment options for patients
with a stage I non-small cell lung cancer (NSCLC). Consequently, there is growing interest in studying the role of
patients in treatment decision making. We studied how patients with stage I NSCLC perceived shared decision
making (SDM) in general, and how they viewed different aspects of SDM.
Methods: A sequential mixed methods design was used, consisting of qualitative interviews (N = 11), as well as a
survey study (N = 76) focusing on different SDM-related aspects. Participants were interviewed to understand their
own experience with treatment decision making. In the survey study, patients rated the importance of 20 aspects
of shared decision making that were identified during interviews. Descriptive analysis and explorative factor analysis
were performed.
Results: We assessed six qualitative themes covering SDM aspects that were determined by patients to be
important. The survey identified four SDM-related factors with sufficient internal consistency, namely (1) ‘guidance
by clinician’ (α = .741), (2) ‘conduct of clinician’ (α = .774); (3) ‘preparation for treatment decision making’ (α = .864);
and (4) ‘active role of patient in treatment decision making’ (α = .782). Of these, clinician guidance was rated as
most important by patients (M = 3.61; SD = .44). Only 28.9 % of patients in the survey study reported that both
treatment options were discussed with them.
Conclusions: Patients with a stage I NSCLC found clinician guidance to be important when making treatment
decisions. Nevertheless, the majority of patients reported not being offered both treatment options, which might
have influenced this finding.
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Background
Shared decision making (SDM) by patients and clini-
cians is a process where clinicians and patients share the
best available evidence and work together to select tests
and treatments, and where patients are supported to
consider options to achieve informed preferences [1, 2].
SDM has been increasingly accepted as a component of
patient-centred high quality care [3, 4]. Studies in
different health contexts indicate that patients prefer a
SDM approach, and wish to be involved in treatment de-
cisions [5, 6]. SDM can also improve a patient’s under-
standing of treatment options, increase confidence in
the decisions made, and result in greater satisfaction
with care provided [7]. SDM is also associated with im-
proved treatment compliance and better quality of life
[8], and it may reduce unwarranted medical practice var-
iations [1, 9, 10], including the overuse of tests and
elective procedures [11]. Consequently, SDM has been
incorporated into the European Cancer Patient’s Bill of
Rights [12], the Patient Protection and Affordable Care
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Act and the Salzburg Statement on Shared Decision
Making [13].
Traditionally, SDM has been advocated for so-called
‘preference sensitive decisions’, which refer to situations
where different, but equally effective, treatment options
are available. In such cases, the ‘correct’ treatment de-
pends on a given patient’s preference, specifically the
relative weight a patient gives to the risks and benefits of
treatment [14, 15]. In the field of oncology, it is increas-
ingly recognized that patients’ preferences may depend
on other aspects than only prolongation of life, for ex-
ample on quality of life [16], which requires a reassess-
ment as to how the decision making process can
optimally be delivered [17].
A current decision problem in oncology is in the treat-
ment of stage I non-small cell lung cancer (NSCLC),
where two guideline-specified curative treatments are
currently available, namely surgery and stereotactic abla-
tive radiotherapy (or SABR) [18]. While surgery is con-
sidered the standard of care in medically operable
patients, many patients are unfit to undergo surgery, or
may decline to do so because of associated-risks. SABR
is the preferred treatment for the latter group of patients
[18]. The rapid growth in use of SABR for this patient
population is because it is an outpatient technique that
is associated with little high-grade toxicity, and long-
term survivals after SABR appear similar to that re-
ported for surgery [19]. Consequently, some clinicians
consider the treatment of stage I NSCLC to be a
preference sensitive decision, with equipoise between
the two options. This, in turn, raises the question as
to how a SDM process for this patient group should
be delivered.
Implementing SDM in clinical practice can be challen-
ging as patients may find participation difficult [7, 20],
or may be ill-prepared for involvement in decision mak-
ing [1]. Such issues may be more pronounced in older
patients with cancer, who may have different expecta-
tions of the decision making process than what is cur-
rently being emphasized in SDM definitions. In general,
patients appear to view SDM as a partnership between
equals [21, 22], expect complete, honest and individual-
ized information [23] and viewed SDM as a process that
respected patient’s views about their health [21, 22, 24].
In contrast, some clinicians appear to view SDM as an
approach to ensure that their patients comply with rec-
ommended treatments, in order to achieve good out-
comes [21, 25]. Several studies have explored whether
older cancer patients wish to be involved in treatment
decision making, and the results have been conflicting.
Some concluded that older cancer patients did prefer a
more paternalistic approach, while others found that the
elderly had a preference for SDM [5, 26, 27]. To the best
of our knowledge, no studies have yet been reported on
how patients with stage I NSCLC view specific aspects
of SDM.
Several instruments have been developed and tested to
assess how the treatment decision making processes
actually occur in healthcare practice, including the ob-
serving patient involvement (OPTION) scale, the 9-item
Shared Decision Making Questionnaire, the Facilitation
of Patient Involvement in Care Scale, the Perceived In-
volvement in Care Scale, the Control Preference Scale
and CollaboRATE [28–33]. Most of the former are
patient-reported measures, and some are observational
measures. Although patient perspectives are usually con-
sidered when developing such instruments, these instru-
ments are generally not well-suited to assess the
importance which patients attach to specific aspects.
The aim of our mixed methods study was to assess the
views of patients with stage I NSCLC on aspects of
SDM considered to be of greatest importance in the de-
cision making process between surgery and SABR. In an
initial interview study, we qualitatively examined how
patients experienced the treatment decision making
process, as well as factors which they found important.
Subsequently, we quantitatively assessed the importance
patients attached to different SDM aspects that had been
identified in a survey study. In addition, we explored
whether differences exist between subgroups of patients
(for example younger (≤65) versus older patients (>65),
males versus females, those with lower educational level
versus those with medium and higher educational levels,
lower health literacy levels versus those with higher
health literacy levels, and those who reported that both
treatment options were discussed versus those who did
not) in their ratings of importance.
Methods
Study design
The prospective study was approved by the Medical
Review Board of the VU University Medical Center
(VUMC) and the Netherlands Cancer Institute - Antoni
van Leeuwenhoek Hospital (NKI-AvL). Eligible partici-
pants had to have a diagnosis of stage I NSCLC no later
than 2–6 months before inclusion, able to converse in
the Dutch language, and provide written informed con-
sent. Patients who underwent either surgery or SABR
were eligible, irrespective of whether they had consid-
ered or rejected the alternative treatment.
A sequential mixed methods design was used [34],
starting with a qualitative interview study conducted
between February and April 2011. Next, the qualita-
tive findings identified were used to design a survey
for a larger patient population treated at the two in-
stitutions. Patients were identified using the institu-
tional databases of the VUMC departments of Radiation
Oncology and Surgery. The interviews focused on how
Hopmans et al. BMC Cancer  (2015) 15:959 Page 2 of 9
patients experienced their own decision making process,
and the factors which they found to be important in this
process. The survey study was performed between
October 2013 and May 2014, and eligible participants
were recruited from the same departments. The survey
captured data on aspects that patients had previously
identified as being important in the qualitative interviews.
Qualitative study
Sixteen eligible patients were invited by a postal letter to
participate, and were subsequently contacted by tele-
phone to assess their willingness to participate. Finally,
11 patients provided written informed consent, and in-
person interviews were performed and audio-taped by
the first author at the VUMC or at the patient’s home.
For qualitative studies, it has been recommended that at
least 8–15 participants be included to collect consistent
data across individuals [35]. As no new topics emerged
after nine interviews, our sample size was considered
large enough to have reached saturation [36, 37]. The in-
terviews were conducted with patients, jointly with rela-
tives if present, using both an open and semi-structured
approach.
In the open phase, we used a visual timeline to facili-
tate the process of telling stories about their healthcare
trajectory and, more specifically, the treatment decision
making process [38]. The interviewer (WH) instructed
participants as follows: “This is a timeline. We are now
at the end of your treatment process. I would like you to
go back to the beginning, where it all started, when you
heard your diagnosis and before a treatment decision
was made. Can you recall and tell me about your experi-
ences?” During the patients’ narrative of the decision
making process, the interviewer made written notes of
patients’ comments. The focus of the interviews empha-
sized two stages of SDM considered essential in the lit-
erature, intended to elicit patient perspectives on
elements of these processes that patients considered
essential: (1) the information collection process and
(2) the decision making process. Examples of inter-
view questions used were: “Can you tell me how the
decision for surgery/SABR was made”; “Can you tell
me how you experienced the process of making the
decision?” Several socio-demographic characteristics
were described to characterize the study population.
Data analysis
Analysis of the data involved the following steps [39, 40]:
(1) The transcribed interviews were read and re-read,
and key ideas on how patients experienced the decision
making process were formed. (2) Two researchers (WH
and OD) then independently analysed four transcripts,
and both developed an initial list of codes. The two re-
searchers held two consensus meetings to compare the
codes and to categorize preliminary themes. (3) Add-
itional transcripts were coded by the first author, and
after consensus meetings, a coding tree was developed.
This coding tree was composed of different subthemes
related to how patients experienced the decision making
process. (4) Sections were re-read to identify patients’
thoughts related to the decision making process. (5) The
final stage involved a process of reflecting on the charted
data to find associations between the themes, to provide
explanations of the findings, and to synthesize the as-
pects that patients found important. Demographic data
were summarized using descriptive statistics in SPSS for
Windows, version 20.0 (SPSS Inc., Chicago, IL).
Quantitative study
A survey developed consisted of importance ratings of
SDM aspects, in a four-point Likert scale from not im-
portant to very important, was identified from the quali-
tative study. These aspects were presented to patients as
being ‘potentially important in the decision making
process’. The survey also measured background charac-
teristics of patients, namely age, sex, education, health
literacy and the treatment which the patient had under-
gone. In addition, they were asked if more treatment op-
tions had been discussed by their treating clinician.
Data analysis
Explorative factor analysis (principal component ana-
lysis) with oblique rotation was performed on the survey
items to determine whether factors could be formed
representing stable aspects of SDM. We constructed
composites, and calculated the internal consistency of
these composites (Cronbach’s alpha). Descriptive ana-
lyses were conducted to assess the average importance
scores on these composites. T-tests were performed to
assess differences between subgroups of patients
(younger (≤65) versus older patients (>65), males ver-
sus females, those with lower educational level versus
those with medium and higher educational levels,
lower health literacy levels versus those with higher
health literacy levels, and those who reported both
treatment options were discussed versus those who did
not). All analyses were performed using SPSS for Win-
dows version 20.0 [SPSS Inc., Chicago, IL).
Results
Table 1 summarises the background characteristics of
patients in both the qualitative and the quantitative
study.
Qualitative study
We identified six main themes representing aspects that
patients found important in the decision making process
about treatment options (Table 2). With regards to the
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information collection process, patients reported that
provision of complete and detailed information was im-
portant, and that information about the disease itself
and possible treatment options needed to be under-
standable (Theme 1: complete and understandable in-
formation). In addition, patients found it important to
search for information themselves, e.g. on the Internet,
and to ask questions to clinicians (Theme 2: active
role of patients in information gathering). Further-
more, patients attached importance to hearing their
clinician’s view on the treatment option in their situ-
ation (Theme 3: hearing preference of the clinician),
particularly as one type of information source to take
into account in decision making. Furthermore, a major
theme was the professional approach by health profes-
sionals that was important to patients (Theme 4: conduct
of professionals), with the affective aspects of being
friendly, thoughtful and respectful, rated as most essential.
Related to this, patients found it important that they
were provided with the opportunity to express their
own opinion and preferences about treatment options
(Theme 5: opportunity to express own opinion). Fi-
nally, patients indicated that it was important that
their family members had a role in the decision mak-
ing process (Theme 6: role of family members), in
particular in supporting the patient in decision mak-
ing. Another finding of importance was that patients
frequently mentioned that the choice between curative
surgery and SABR had not been offered.
Quantitative study
The survey assessed the main themes identified in the
qualitative study, which were then translated into 20





(n = 11) Interviews
Number of patients
(N = 76) Survey
% (n) % (n)
Age <50 9 (1) 0 (0)
50-64 18 (2) 17 (13)
65-74 27 (3) 33 (25)
≥75 46 (5) 46 (35)
Missing 0 (0) 4 (3)
Sex Male 46 (5) 62 (47)
Female 54 (6) 36 (27)
Missing 0 (0) 3 (2)
Educationa Low 36 (4) 37 (28)
Medium 27 (3) 38 (29)
High 36 (4) 24 (18)
Missing 0 (0) 1 (1)
Health Literacyb Low 27 (3) 54 (71)
High 73 (8) 21 (28)
Missing 0 (0) 1 (1)
Treatment Surgery 45 (5) 22 (17)
SABR 55 (6) 74 (56)
Missing 0 (0) 4 (1)
aLow: primary school, lower level of secondary school or lower vocational
training. Medium: higher level of secondary school, or intermediate vocational
training. High: higher vocational training or university. bQuestion “How
confident are you filling out medical forms yourself” [56, 57]: Low health
literacy: patients answered: some of the time, a little of the time or none of
the time. High health literacy: patients answered: all of the time, most of
the time
Table 2 Themes derived from the qualitative study
Information collection process
Theme 1: Complete and understandable information
“I think it is important that a clinician is open to a patient. That they do
not refrain from providing information. Nowadays, clinicians pay more
attention to this than in the past. But clinicians are different in that. I’m
lucky because my surgeon explains everything very thoroughly and in a
straightforward way. I appreciate that ”. F, 69y
“I think it is important that they < e.g. clinicians > explain everything in an
understandable way. No fancy Latin names that patients do not understand
and that results in saying to yourself when you are out of the office: I have
cancer, but I don’t know what they are going to do. For me it is important
that I understand everything”. M, 66y
Theme 2: Active role of patients in information gathering
“In advance, I made a list with questions I wanted to ask the clinician. Are
there alternatives, is it an option to do nothing? I wrote 5 or 6 issues down.
I came well-prepared” F, 66y
“I read a lot on the Internet in that time period and I am pleased with
that information and knowledge because I can actively take part in the
conversation with the clinician” F, 66y
Theme 3: Hearing preference of the clinician
“Initially, they scheduled me for SABR, because of the fact that there was
little tissue damage. During the second consultation with the clinician, I
asked him, what would you advice your own father? Then he said: surgery”.
M, 62y
“And then my oncologist said to me, it is your decision, what do you want?
Then I said, what do you recommend?”. M, 80y
Decision making process
Theme 4: Conduct of professionals
“Many of the consultations with a clinician are technical. And they forget
to feel compassion for a patient. There is no time to do that. When a
clinician is very kind, that is 20 % of your recovery. Only being nice. And
when he is disrespectful , you decline with 20 %”. F, 66y
“In my opinion, it is important that a clinician is able to communicate with
people, able to talk and to listen. And when you are not able to do that,
you are a worthless clinician”. M, 78y
Theme 5: Opportunity to express own opinion
“The clinician wanted to operate immediately. I said, I want to think about
that first. There’s also the option of radiotherapy” F, 69y
“They < clinicians > wanted to operate me. I felt that my body wasn’t ready
for another operation. Then I said that I wanted a second opinion. I
wanted that very badly” F, 63y
Theme 6: Role of family members
“When it was clear what SABR was about and that it was 1 to 5 times, I
clearly mentioned to my father, you can do that” Daughter of M, 78y
“My husband joins me. We complement each other. We do all these things
together. When there is something wrong with him I go along and when
there is something wrong with myself, he goes along”. F, 80y
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survey items. We derived three items from theme 1,
three items from theme 2, three items from theme 3,
seven items from theme 4, three items from theme 5,
and one item from theme 6 (Table 3). The disproportion
in the numbers of items was related to the variety of
specific aspects addressed by patients in discussing each
theme. For example, patients mentioned a great variety
of specific aspects related to professional conduct of cli-
nicians, whereas they mainly addressed support during
the decision making process when discussing the role of
family members.
In total, 76 of 150 (50.7 %) patients who were
approached finally completed the survey, with response
rates for patients who had undergone surgery being
22.4 % (N = 17), and for SABR patients 73.7 % (N = 56).
Three respondents did not answer the question about
the treatment which they had undergone. A total of
28.9 % of patients reported that both treatment options
had been discussed by their clinician.
Factor analysis
Table 4 presents the details of the factor solution of all
items and the resulting construction of composite mea-
sures. We identified four factors with both sufficient
internal consistency and item clarity: (1) ‘guidance by
the clinician’ (α = .741), (2) ‘conduct of clinician’ (α
= .774); (3) ‘preparation for treatment decision making’ (α
= .864); and (4) ‘active role of patient in treatment decision
making’ (α = .782). Two items could not be included in
these composite measures, namely ‘friendliness of the
clinician’ and ‘you give your clinician information about
how you experience your disease’. The factor loadings of
these two items were low (<0.4) and the internal
consistency of the composite measures did not improve
when including them in these factors.
The mean importance scores on the composite mea-
sures and individual items are displayed in Table 5. Pa-
tients found ‘guidance by the clinician’ most important
(M = 3.61; SD = .44). This composite covered items such
‘your clinician gives you advice about the best treatment
option for you’ and ‘the treatment that best fits for you
is chosen’. The factor ‘active role of patient in treatment
decision making’ was reported to be least important
(M = 2.75; SD = .71). No significant differences were
observed between subgroups of patients (younger
(≤65) versus older patients (>65), males versus females,
those with lower educational level versus those with
medium and higher educational levels, lower health lit-
eracy levels versus those with higher health literacy
levels, and those who reported both treatment options
were discussed versus those who did not) in their im-
portance ratings of the constructs, nor for the individ-
ual items.
Discussion
In this sequential mixed methods study examining how
patients with stage I NSCLC perceive SDM, ‘guidance by
the clinician’ was identified by patients as being the most
important, and an active role by patients was considered
relatively less important. A majority of patients (71.1 %)
reported not being offered both treatment options (sur-
gery and SABR), indicating that SDM was not taking
place in many consultations.
Both qualitative and quantitative data revealed that pa-
tients considered the ‘expert’ advice from their clinician
of great importance in the decision making process, a
Table 3 Link between qualitative themes and quantitative items
Qualitative themes Quantitative items
Do you think it is important for your decision that …
Theme 1: Complete and understandable information … you receive information from your clinician about all possible treatment options?… you
receive information from your clinician about your disease?…your clinician gives you
information about your disease that is understandable?
Theme 2: Active role of patients in information gathering … you give your clinician information about how you experience your disease?… you search
for information (for example on the Internet) about possible treatment options?… you ask the
questions you have?
Theme 3: Hearing preference of the clinician … you follow your clinician in the proposed treatment advice?… you decide together
with your clinician about your treatment?… your clinician gives you advice about the best
treatment option for you?
Theme 4: Conduct of professionals … your clinician takes you seriously?… your clinician takes time for you?… your clinician is
friendly?… your clinician asks you about your situation at home?… your clinician provides
the opportunity to ask questions?… your clinician takes your treatment preferences
seriously?… you receive time from your clinician to think about what treatment you want
to have?
Theme 5: Opportunity to express own opinion … your clinician asks you what you think of the different treatment options?… your
clinician lets you decide what treatment you want to undergo?… the treatment that best
fits for you is chosen?
Theme 6: Role of family members … you eventually decide with your family what treatment you want to have?
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finding similar to that reported in other studies in pa-
tients with cancer [26, 27]. This finding is in contrast
with formal definitions of SDM, which envisage a more
active role for patients. The importance attached to
guidance by clinicians may partly be accounted for by
the fact that a majority of patients had no treatment op-
tions presented to them. If clinicians fail to have a
‘choice talk’ [41] with patients, in which it is ex-
plained that they are in a position to choose between
treatment options, patients may end up attaching
more importance to guidance by clinicians. A prefer-
ence for a less active role might also be explained by
a perceived lack of skills needed to participate in
treatment decision making. For example, older pa-
tients have been found to have relatively more diffi-
culties with processing information about treatment
options [42]. In addition, more traditional attitudes
(i.e., “the doctor knows best”) and lower motivation
and ability to participate in decisions may be relevant
factors [43–45].
Patients also considered the approach and conduct of
the clinician (i.e., being emphatic/affective in communi-
cation), as being highly important in the context of treat-
ment decision making. Affective communication aspects
are recognized to be important to patients [46, 47], and
our findings again emphasize the importance of support-
ive clinicians in the treatment decision making process.
Although current definitions of SDM usually include
supportive or ‘coaching’ elements, these seem to differ
from the more guiding role that patients referred to in
our study. For example, the International Patient
Decision Aids Standards (IPDAS) criteria on coaching
and guidance include assessing decisional needs, provid-
ing information, verifying understanding, clarifying pref-
erences, building skills, screening for implementation
needs, and facilitating progress in decision making [48].
These aspects do not directly cover conduct-related as-
pects. In clinical practice, the focus of SDM relies more
on information provision from the clinician about alter-
native treatment options, with the patient giving and
Table 4 Construction of scales with factor solutions and reliability analysis of 20 interview-based items
Factor loading ITCa α if item deleted
Do you think it is important for your decision that…
Construct 1: Guidance by the clinician (α = .741)
… your clinician gives you advice about the best treatment option for you? .850 .566 .656
… the treatment that best fits for you is chosen? .562 .590 .646
… you ask the questions you have? .528 .572 .669
Construct 2: Conduct of clinician (α = .774)
… your clinician takes you seriously? .866 .677 .683
… your clinician takes time for you? .828 .723 .651
… your clinician takes your treatment preferences seriously? .591 .479 .800
… your clinician provides opportunity to ask questions? .444 .514 .751
Construct 3: Preparation for treatment decision making (α = .864)
… you receive information from your clinician about all possible treatment options? .847 .741 .827
… you receive information from your clinician about your disease? .832 .584 .856
… you follow your clinician in the proposed treatment advice? .781 .767 .823
… you decide together with your clinician about your treatment? .761 .675 .839
… your clinician asks you what you think of the different treatment options? .594 .643 .849
… your clinician gives you information about your disease that is understandable? .539 .611 .852
Construct 4: Active role of patient in treatment decision making (α = .782)
… you receive time from your clinician to think about what treatment you want to have? .720 .706 .697
… you search for information (for example on the Internet) about possible treatment options? .695 .398 .798
… you eventually decide with your family what treatment you want to have? .665 .631 .715
… your clinician lets you decide what treatment you want to undergo? .522 .539 .747
… your clinician asks you about your situation at home? .494 .551 .744
aItem Total Correlation
The suitability of data for factor analysis was assessed by inspection of the correlation matrix, by computing the Kaiser-Meyer-Olkin measure of sampling adequacy
value (KMO) and by running the Bartlett’s Test of Sphericity. KMO was .774 and Bartlett’s Test of Sphericity was < .00. KMO values of .60 or greater and a significant
Bartlett’s Test of Sphericity for factor analysis were considered appropriate. An eigenvalue of 1.00 or greater was adopted as cut-off point to determine the number
of components. An item’s factor loading of > .4 was used as a cut-off point for inclusion, followed reliability evaluation by calculations of Cronbach’s alpha
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clarifying his or her preferences and values [41]. These
SDM conceptions might not sufficiently take account of
patients’ need for empathic communication styles of
health professionals in making decisions.
Our finding that most patients were not provided with
both options by their clinicians is consistent with a re-
cent binary choice experiment among thoracic oncolo-
gists that showed that 45 % of thoracic oncologists did
not consider surgery and SABR equal treatment options
for stage I NSCLC patients, and that the patient’s prefer-
ence did not heavily influence clinicians’ treatment rec-
ommendations [49]. The main reason for not
considering both options to be equal was the perception
that there is insufficient evidence, as no completed ran-
domized controlled trials have been reported [49]. How-
ever, as the available comparative effectiveness data
clearly suggest that SABR results in comparable out-
comes to surgery [19, 50], and as guidelines [18] have
taken this into account, more effort should be under-
taken to increase awareness of this equipoise of options,
for example during professional training of clinicians.
One limitation of our study was the relatively low re-
sponse rate in the survey study. Although our number of
respondents (N = 76) is considered acceptable for princi-
pal component analysis [51], some guidelines recom-
mend higher numbers of respondents [52]. In addition,
only 22 % of respondents had undergone surgery
whereas 74 % were post-SABR patients, which might
bias our findings. The reluctance of surgical patients to
participate may, in part, be a reflection of the significant
decline in quality of life following surgery in the post-
surgical period, and in particular symptoms that persist
in the first 6-months post-surgery [53]. In the
Netherlands, fewer than 50 % of patients aged 70 years
and older currently undergo surgery [54]. No differences
were observed between patients who had undergone sur-
gery and SABR patients in the importance attached to
the SDM aspects, but the relatively small number of sur-
gical patients should be noted. Our quantitative findings
should also be interpreted in light of the fact that less than
a third of patients described being offered both treatment
options. Nevertheless, no significant differences were
found between those who had been offered both options
and those who had not been offered both options.
Our factor analysis revealed that four factors generally
represented the dimensional structure of the survey in a
stable way. However, ‘preparation for treatment decision
making’ included two items (i.e. ‘your clinician asks you
what you think of the different treatment options’ and
‘you follow your clinician in the proposed treatment’) on
treatment discussion with the clinician that, when based
on substantive arguments, might also suit to ‘guidance
by the clinician’. Finally, recall bias could have been
present as participants were included 2–6 months after
hearing their diagnosis. Moreover, patient recall may also
be influenced by their satisfaction with the treatment
chosen and/or the healthcare process [55].
Conclusions
Patients with a stage I NSCLC found guidance of clini-
cians, as well as their affective conduct, to be important
in the treatment decision making process. Less than a
Table 5 Average importance scores of the 20 interview-based
items
M (SD)
Do you think it is important for your decision that…
Construct 1: Guidance by the clinician (α=,741) 3.61 (.44)
… your clinician gives you advice about the best treatment
option for you?
3.68
… the treatment that best fits for you is chosen? 3.71
… you ask the questions you have? 3.45
Construct 2: Conduct of clinician (α=,774) 3.53 (.46)
… your clinician takes you seriously? 3.68
… your clinician takes time for you? 3.64
… your clinician takes your treatment preferences seriously? 3.29
… your clinician gives space to ask questions? 3.51
Construct 3: Preparation for treatment decision making
(α=,864)
3.46 (.49)
… you receive information from your clinician about all
possible treatment options?
3.51
… you receive information from your clinician about your
disease?
3.66
… you follow your clinician in the proposed treatment
advice?
3.30
…you decide together with your clinician about your
treatment?
3.51
… your clinician asks you what you think of the different
treatment options?
3.14
…your clinician gives you information about your disease
that is understandable?
3.63
Construct 4: Active role of patient in treatment decision
making (α=,782)
2.75 (.71)
… you receive time from your clinician to think about what
treatment you want to have?
3.05
… you search for information (for example on the Internet)
about possible treatment options?
2.14
… you eventually decide with your family what treatment
you want to have?
2.78
… your clinician let you decide what treatment you want
to undergo?
2.88
… your clinician asks you about your situation at home? 2.91
Other items:
… your clinician is friendly? 3.39
…you give your clinician information about how you
experience your disease?
3.28
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third of our patients were in fact offered both treatment
options, a finding which might have biased the observed
findings. It appears necessary that current SDM concep-
tions and guidelines should address such guidance and
clinician conduct more explicitly.
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